Drug Trial Radar · NCT07118709
A Study of KC1086 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Aug 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety,tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into two parts: dose-escalation phase and dose-expansion phase.
Conditions
- Advanced Solid Tumors Cancer
Interventions
KC1086Drug
Part 1: Dose-escalation phase , five dose groups are included: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg. Part 2: Dose-expansion phase, 2 to 3 dose levels will be selected for expansion based on the results of the dose escalation phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: approximately 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.